1.3+4 Population Science Clinical Trials Flashcards Preview

Yr 2 Sem 2 CPT > 1.3+4 Population Science Clinical Trials > Flashcards

Flashcards in 1.3+4 Population Science Clinical Trials Deck (63)
Loading flashcards...
1
Q

What do phase 1 studies detect?

A

Pharmacodynamics
Pharmacokinetics
Major side effects

2
Q

What do phase 2 studies aim to detect?

A

Effects and dosages

Common side effects

3
Q

What do phase 4studies aim to detect?

A

Monitoring for adverse reactions

Potential new uses

4
Q

What type of risk does scientifically proven refer to?

A

Relative risk

5
Q

What type of study are clinical trials?

A

Cohort study

Exposed and unexposed then count outcome events and person years

So do new treatments and standard treatment and then measure the outcomes over time

6
Q

Define a clinical trial

A

Any for, of planned experiment which involves patients and is designed to elucidate the most appropriate method of treatment for FUTURE patients with a given medical condition

7
Q

What is the purpose of a clinical trial?

A

To provide reliable evidence of treatment efficacy and safety

8
Q

Define efficacy

A

The ability of a health care intervention to improve the health of a defined group under specific conditions

9
Q

Define safety

A

The ability of a health care intervention not to harm a defined group under specific conditions

10
Q

What does a Control in a clinical trial mean?

A

It means that there is a comparison

NOT that everything is controlled

11
Q

What three things should a clinical trial be to be able to give a fair comparison of effect and safety?

A

Reproducible
Controlled
Fair

12
Q

What does the observed rate ratio mean?

A

If the null hypothesis value is consistent with the observed data, then any observed difference from the null hypothesis may be due to chance

13
Q

What is randomisation?

A

Having an equal chance of being put into group A or group B

14
Q

What do non randomised clinical trials involve?

A

The allocation of patients receiving a new treatment to compare with a group of patients receiving the standard treatment

15
Q

What are two problems with non randomised clinical trials?

A

Allocation bias

Confounding (known and unknown)

16
Q

What is a benefit of RCT in terms of confounding?

A

Randomising reduces confounding
This includes confounding factors that were unknown at the time
This works as long as the sample size was large enough

17
Q

What are some of the issues with the standard treatment group when using historical controls?

A

Selection often less well defined and less rigorous
Treated differently from new treatment group
Less information about bias and confounders
Unable to control for confounders

18
Q

What factors must be controlled in a RCT?

A
Disease of interest
Treatments to be compared
Outcomes to be measured 
Possible bias and confounders 
The patients eligible for the trial 
The patients to be excluded from the trial
19
Q

What steps are involved for conduct of the trial?

A

Identify a source of eligible patients
Invite eligible patients to be in the trial
Consent patients willing to be in the trial
Allocate participants to the treatments fairly
Follow up participants in identical ways
Minimise losses to follow up
Maximise compliance with treatments

20
Q

How can you tell if a trial is statistically significant?

A

Could the observed difference have originated by chance?

Related to p value and 95% confidence interval

21
Q

How can you tell whether a trial is clinically important?

A

How big is the observed difference between the treatment groups?
Need to have a big enough study group

22
Q

Why do you need to predefine outcomes for a clinical trial?

A

Prevent data dredging and repeated analyses
Protocol for data collection
Agreed criteria for measurement and assessment of outcomes

23
Q

What is data dredging?

A

Looking back at studies, at very small groups, to find an effect

24
Q

What is the primary outcome used in?

A

Sample size calculation

25
Q

What are three groups of outcomes?

A

Pathophysiological
Clinically defined
Patient focussed

26
Q

Name some pathophysiological outcomes?

A

Tumour size
Thyroxine level
ECG changes

27
Q

Name some clinically defined outcomes

A

Death (mortality)
Disease (morbidity)
Disability

28
Q

Name some patient focussed outcomes

A

Quality of life
Psychological well-being
Social well being
Satisfaction

29
Q

What are some features of an ideal outcome?

A

Appropriate and relevant
Valid and attributable - any observed effect can be reasonably be linked to compared treatments
Sensitive and specific
Reliable and robust- outcome measurable by different people in different settings
Simple and sustainable - method of measurement easily carried out repeatedly
Cheap and timely

30
Q

What is non random allocation?

A

Allocation of participants to treatments by a person, historical basis, geographical location, convenience, numerical order

31
Q

What is a problem with non random allocation?

A

Leads to the potential for allocation [aka. selection] bias and confounding factors to unwittingly cause unidentified differences between the treatment groups being compared

Non random allocation -> allocation bias and confounding

32
Q

What are the advantages of random allocation?

A

Minimal allocation bias
- Each participant has an equal chance of being allocated to either treatment
Minimal confounding
- Treatment groups likely to be similar in size and characteristics by chance
For known and unknown factors

33
Q

What is the issue with open label?

A

Knowledge of which participant is receiving which treatment may bias the results of a clinical trial

34
Q

What is a behaviour effect?

A

Patient may alter their behaviour, other treatment, or expectation of outcome due to open label trial

35
Q

What is the non treatment effect?

A

Clinician may alter their treatment, care and interest in the patient in an open label trial

36
Q

What is measurement bias?

A

Investigator may alter their approach when making measurements and assessing outcomes in open label trials

37
Q

What are some examples of where blinding may be difficult?

A
Surgical procedures 
Psychotherapy vs antidepressant 
Alternative medicine vs western medicine 
Lifestyle interventions 
Prevention programmes
38
Q

What is the placebo effect?

A

Even if the therapy is irrelevant to the patient’s condition, the patient’s attitude to his or her illness, and indeed the illness itself, may be improved by a feeling that something is being done about it

39
Q

What is a placebo?

A

An inert substance made to appear identical in every way to the active formulation with which it is being compared
Eg appearance, taste, texture, dosage regime, warnings

40
Q

What is the aim of a placebo?

A

Cancel out any placebo effect

41
Q

What are the ethical implications of placebo?

A

A placebo should only be used when no standard treatment is available
Use of placebo is a form of deception
All participants should be told they may get a placebo

42
Q

What are the two types of losses to follow up?

A

Appropriate- Their clinical condition may necessitate their removal from the trial

Unfortunate - They may choose to withdraw from the trial

43
Q

How can you minimise losses to follow up?

A

Make follow up practical and convenient
Be honest about the commitment required from participants
Avoid coercion or inducements
Maintain contact with participants

44
Q

Why may some patients be non compliant?

A
Mis understoo instructions 
Not like taking treatment 
Think treatment doesn’t work 
Cant be bothered
Prefer other treatments
45
Q

How can compliance be maximised?

A

Simplify instructions
Ask about compliance
Ask about effects and side effects
Monitor compliance eg tablet count, urine and blood levels

46
Q

What is as treated analysis?

A

Analyse according to whether they took the treatment
This is an explanatory trial

Analyses only those who completed follow up and complied with treatments
Compared the physiological effects of the treatments

47
Q

What is the problem with an explanatory trial?

A

Looses effect of randomisation

Non compilers likely to be systematically different from compliers leading to selection bias and confounding

48
Q

What is intention to treat analysis?

A

Analyses according to the original allocation to treatment groups regardless of whether they completed follow up and complied

Compares the likely effects of using the treatments in routine clinical practice

Includes people that didn’t take the treatment as don’t know if people who took the treatment definitely took it

49
Q

What is the advantage of a pragmatic trial?

A

Preserves effects of randomisation so minimal selection bias and confounding

50
Q

What are the impacts on size of effect for as treated vs intention to treat

A

As treated give larger sizes of effect

Intention to treat give smaller more realistic sizes of effect

51
Q

What type of analysis should clinical trials use?

A

Intention to treat

52
Q

What is collective ethic?

A

All patients should have treatments that are properly tested for efficacy and safety

53
Q

What is individual ethic?

A

The principles of beneficence, non-maleficence, autonomy and justice

54
Q

Who do RCTs benefit?

A

Future patients

55
Q

Why do RCTs not display individual ethic?

A

They do not guarantee benefit
They may result in harm
They allocate treatment by chance
They place burdens and confer benefits

56
Q

What issues should be considered for a clinical trial to be ethical?

A
Clinical equipoise
Scientifically robust
Ethical recruitment 
Valid consent
Voluntariness
57
Q

What is clinical equipoise?

A

when there is reasonable uncertainty or genuine ignorance about the better treatment or intervention (including non- intervention)

58
Q

What factors contribute to making a trial scientifically robust?

A

Addresses relevant or important issue
Asks a valid question
Appropriate study design and protocol
Can justify use of the comparator treatment or placebo
Acceptable risks of possible harm compared to anticipated benefits
Provision for monitoring the safety and well being of trial participants
Arrangements for appropriate reporting and publication

59
Q

What are the two issues surrounding ethical recruitment?

A

Inappropriate INCLUSION of

  • people unlikely to benefit
  • people with a high risk of harm compared to benefits eg pregnant women
  • people likely to be excluded from analysis eg small sub groups

Inappropriate EXCLUSION of

  • people who differ from ideal homogenous group eg co morbidity, elderly
  • people who are difficult to get valid consent from eg immigrants, children, mentally ill
60
Q

What things are required to gain valid consent?

A

Knowledgeable informant
Appropriate information with cooling off period
Informed participant who is a competent decision maker and a legitimate authoriser

61
Q

When may a signed consent form not equate to valid consent?

A

If it can be shown that the explanation was not adequate or if there was coercion

62
Q

What are some examples of coercion?

A

Non access to best treatment, lower quality of care, disinterest by clinician

63
Q

What are some examples of manipulation?

A

Exploitation of emotional state, distortion of information, financial inducements